Walder Wyss advises global aesthetic manufacturer Teoxane Laboratories on Exclusive U.S. Distribution Agreement of FDA-Approved RHA Dermal Fillers with Revance Therapeutics, Inc.
10. Januar 2020 – Geneva, Switzerland – Teoxane SA, Swiss laboratories specializing in Hyaluronic Acid dermal fillers, announced today the signing of an exclusive U.S. distribution agreement with Revance Therapeutics, Inc. (Nasdaq: RVNC), making Revance the exclusive commercialization partner of the Swiss company’s modern and innovative Resilient Hyaluronic Acid® (RHA®) preserved network technology.
Walder Wyss advised TEOXANE SA in this transaction. The team was led by Pierre-Alain Guillaume (Partner, Tax) and included Patrick W. Vogel (Partner, Corporate/M&A), Adriano Antonietti (Partner, Corporate/M&A), Monique Sturny (Managing Associate, Pharma/IP), Nicolas F. Krauer (Senior Associate, Corporate/M&A), Annemarie Lagger (Associate, IP/IT) and Gabrielle Guye (Associate, Tax).